52854-14-5

Basic information

• Product Name: 4-CHLORO-6-METHOXY-5-NITROPYRIMIDINE
• Synonyms: 4-CHLORO-6-METHOXY-5-NITROPYRIMIDINE;NSC 73560
• CAS NO: 52854-14-5
• Molecular Formula: C₅H₄ClN₃O₃
• Molecular Weight: 189.56
• EINECS: 604-604-1
• Mol File: 52854-14-5.mol
• Article Data: 8

Chemical Properties

• Melting Point: 66℃
• Boiling Point: 343.1°C at 760 mmHg
• Flash Point: 161.3°C
• Appearance: /
• Density: 1.532g/cm³
• Vapor Pressure: 0.000143mmHg at 25°C
• Refractive Index: 1.569
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -4.87±0.26(Predicted)
• CAS DataBase Reference: 4-CHLORO-6-METHOXY-5-NITROPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-6-METHOXY-5-NITROPYRIMIDINE(52854-14-5)
• EPA Substance Registry System: 4-CHLORO-6-METHOXY-5-NITROPYRIMIDINE(52854-14-5)

Safety Data

• Hazardous Substances Data: 52854-14-5(Hazardous Substances Data)

Usage

General Description

4-CHLORO-6-METHOXY-5-NITROPYRIMIDINE is a chemical compound that belongs to the pyrimidine family. It is characterized by a chloro group at position 4, a methoxy group at position 6, and a nitro group at position 5 of the pyrimidine ring. 4-CHLORO-6-METHOXY-5-NITROPYRIMIDINE is commonly used in the pharmaceutical and agricultural industries for the synthesis of various drugs and pesticides. Its chemical structure and properties make it useful for its biological activities, including antimicrobial and antiparasitic properties. It is also used as an intermediate in the production of other pyrimidine-based compounds. Additionally, it has potential applications in the field of medicinal chemistry and drug discovery due to its biological activity and structural versatility.

InChI:InChI=1/C5H4ClN3O3/c1-12-5-3(9(10)11)4(6)7-2-8-5/h2H,1H3

Upstream product

• 67-56-1 methanol 
• 4316-93-2 4,6-dichloro-5-nitropyrimidine 
• 124-41-4 sodium methylate 

Downstream Products

• 136038-68-1 1-phenyl-2-dimethylaminomethyl-3-ethoxycarbonyl-5-(5'-nitro-6'-methoxypyrimid-4'-yl)oxyindole 
• 136038-70-5 2-Diethylaminomethyl-5-(6-methoxy-5-nitro-pyrimidin-4-yloxy)-1-phenyl-1H-indole-3-carboxylic acid ethyl ester 
• 136038-72-7 2-Diethylaminomethyl-5-(6-methoxy-5-nitro-pyrimidin-4-yloxy)-1-p-tolyl-1H-indole-3-carboxylic acid ethyl ester 
• 136038-73-8 2-Diethylaminomethyl-5-(6-methoxy-5-nitro-pyrimidin-4-yloxy)-1-(4-methoxy-phenyl)-1H-indole-3-carboxylic acid ethyl ester 
• 77696-41-4 5-nitro-4-methoxy-6-(2,2-diphenylhydrazino)pyrimidine 
• 689298-05-3 3'-(1-methyl-5-nitro-6-oxo-1,6-dihydropyrimidin-4-ylamino)biphenyl-2-carbonitrile 
• 15579-82-5 4-methoxy-pyrimidin-5-ylamine 
• 148214-81-7 5-acetylamino-4-iodo-6-methoxy-2-methylpyrimidine 
• 144216-57-9 4-methoxy-5H-pyrrolo<3,2-d>pyrimidine 
• 100114-07-6 (6-methoxy-5-nitro-pyrimidin-4-yl)-methyl-amine 
• 136038-67-0 5-(6-Methoxy-5-nitro-pyrimidin-4-yloxy)-1-(4-methoxy-phenyl)-2-methyl-1H-indole-3-carboxylic acid ethyl ester 
• 136038-63-6 1-phenyl-2-methyl-3-ethoxycarbonyl-5-(5'-nitro-6'-methoxypyrimid-4'-yl)oxyindole 

Relevant articles and documents

Discovery of 5-Nitro-6-thiocyanatopyrimidines as Inhibitors of Cryptococcus neoformans and Cryptococcus gattii

Opportunistic infections from pathogenic fungi present a major challenge to healthcare because of a very limited arsenal of antifungal drugs, an increasing population of immunosuppressed patients, and increased prevalence of resistant clinical strains due to overuse of the few available antifungals. Cryptococcal meningitis is a life-threatening opportunistic fungal infection caused by one of two species in the Cryptococcus genus, Cryptococcus neoformans and Cryptococcus gattii. Eighty percent of cryptococcosis diseases are caused by C. neoformans that is endemic in the environment. The standard of care is limited to old antifungals, and under a high standard of care, mortality remains between 10 and 30%. We have identified a series of 5-nitro-6-thiocyanatopyrimidine antifungal drug candidates using in vitro and computational machine learning approaches. These compounds can inhibit C. neoformans growth at submicromolar levels, are effective against fluconazole-resistant C. neoformans and a clinical strain of C. gattii, and are not antagonistic with currently approved antifungals.

Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases

New pyridin-2(1h)-one derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES

[Purpose] The present invention provides compounds useful as agents for the prevention or treatment of a sex hormone-dependent disease or the like. [Solution] The present invention provides nitrogen-containing fused ring derivatives represented by the following general formula (I) which has a GnRH antagonistic activity, prodrugs, salts, pharmaceutical compositions containing the same, medicinal uses thereof and the like. In the formula (I), rings A and B are independently aryl or heteroaryl; RA and RB are independently halogen, cyano, alkyl, alkylsulfonyl, -OW1, -SW1, -COW2, -NW3W4, -SO2NW3W4, aryl, etc.; RC is H or alkyl; E is oxygen atom, etc.; U is single bond or alkylene; and X is Y, -CO-Y, -SO2-Y -S-(alkylene)-Y, -O-(alkylene)-Y, -SO2-(alkylene)-Y, etc.; Y is Z or amino, etc.; and Z is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.